Left atrial appendage closure vs oral anticoagulation for atrial fibrillation: PRAGUE 17: 4 years

Objective

to report the 4-year follow-up clinical outcomes comparing left atrial appendage closure (LAAC) with non-warfarin oral anticoagulation for (DOAC) atrial fibrillation (WATCHMAN or AMULET)

Study

prospective multicentre randomised non-inferiority trial (margin 5%)

Population

patients with nonvalvular AF at moderate or high risk for stroke or bleeding (CHA2DS2-VASc ≥3 plus HAS-BLED ≥2)

Endpoints

composite of stroke or TIA, systemic embolism, clinically significant bleeding, death or periprocedural complication